NEW YORK, April 19 (Reuters) – As Valeant Pharmaceuticals
considers a multibillion-dollar auction to pare down $30 billion
in debt, its challenge will be choosing which assets to sell
without…
The post DEALTALK-Debt-laden Valeant faces tough choices in asset sales appeared first on NASDAQ.